References
- (GOLD), Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (cited 2019 Jul 22. s.l. Available from: www.goldcopd.org Report.
- Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J COPD. 2018;13:3115–3130.
- Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
- Sethi S, Cote C. Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease. Curr Clin Pharmacol. 2011;6(1):48–61.
- Highlights of Prescribing Information. [ Online]. 2013 [cited 2019 July 22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203975s000lbl.pdf
- Highlights of Prescribing Information. [ Online]. 2015 [cited 2019 July 25]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206756s009lbl.pdf
- Highlights of Prescribing Information. [ Online]. 2015 [cited 2019 July 25]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207930s000lbl.pdf
- Highlights of Prescribing Information. [ Online]. 2016 [cited 2019 July 22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdf
- Highlights of Prescribing Information. [ Online]. 2019 [cited 2019 July 22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210595lbl.pdf
- Database, National Center for Biotechnology Information. PubChem. Aclidinium bromide. [ Online] [cited 2019 Jun 20] https://pubchem.ncbi.nlm.nih.gov/compound/Aclidinium-bromide
- Caulfield MP, Birdsall NJM. International union of pharmacology. XVII. classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279–290.
- Pisano M, Mazzola N. Aclidinium bromide inhalation powder (tudorza): a long-acting anticholinergic for the management of chronic obstructive pulmonary disease. Pharm Ther. 2013;38(7):393–396.
- Formoterol fumarate. [ Online] [cited 2019 Jun 28] https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus⊄NCI_Thesaurus&code=C47540
- AstraZeneca. Tudorza pressair highlights of prescribing information (aclidinium bromide inhalation powder). [ Online] 2019 April. [cited 2019 Jun 29] https://www.azpicentral.com/tudorza/tudorza.pdf#page=1dmd.aspetjournals.org/content/27/10/1104
- Petzold U, Kremer HJ, Nguyen DT, et al. Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2008;21:309–319.
- Merck & Co., Inc. FORADIL AEROLIZER (formoterol fumarate inhalation powder) Highlights of Prescribing Information. [ Online] 2012 Sep. [Cited 2019 Jun 22.] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020831s028lbl.pdf.
- Rosenborg J, Larsson P, Tegner K, et al. Mass balance and metabolism of [(3)H]formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. Drug Metab Dispos. 1999;27(10):1104–1116.
- Fuhr R, Leselbaum A, Aubets J. Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: a phase 1, open-label, single-dose study. Clin Pharmacol Drug Dev. 2016;5(2):109–117.
- D D’Urzo A, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. BMC Respir Res. 2014;15:123.
- Sethi S, Kerwin E, Watz H, et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J COPD. 2019;14:667–682.
- Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–977.
- Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92.
- Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
- Garcia-Rio F, Rojo B, Casitas R, et al. Prognostic value of the objective measurement of daily physical activity in patients with COPD. Chest. 2012;142:338–346.
- D’Urzoa A, Rennard S, Kerwin E, et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med. 2017;125:39–48.
- Donohue JF, Soong W, Wu X, et al. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD. Respir Med. 2016;116:41–48.
- Watz H, Troosters T, Beeh KM, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J COPD. 2017;12:2545–2558.
- Pascual S, Feimer J, De Soyza A, et al. Preference, satisfaction and critical errors with genuair air breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. NPJ Prim Care Respir Med. 2015;25.
- Wise RA, Chapman KR, Scirica BM, et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease; the ASCENT-COPD randomized clinical trial. JAMA. 2019;321(17):1693–1701.